ORKA

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2003, for Nuvelo, Inc. (formerly Hyseq, Inc.). The company is a biopharmaceutical firm focused on the discovery and development of novel protein-based products. A material event during this period was the completion of a merger with Variagenics, Inc. on January 31, 2003, which significantly altered the company's asset base and cash position. The financial results for the quarter include Variagenics' operations commencing from February 1, 2003.

Key Financial Metrics

Note: Total Debt includes a $11.0 million line of credit, $2.6 million short-term note, and $4.0 million long-term note payable as of March 31, 2003.

Material Changes vs. Prior Period

• Liquidity Surge: Cash and short-term investments increased from $2.225 million (Dec 31, 2002) to $41.265 million (March 31, 2003). This was primarily driven by the acquisition of Variagenics, which contributed approximately $50.8 million in cash and short-term investments.
• Revenue Decline: Contract revenues dropped 75% year-over-year. This decrease is attributed to the accelerated completion of a collaboration with BASF Plant Sciences in late 2002, which generated significant revenue in the prior year but none in the current quarter.
• Expense Reduction: Total operating expenses decreased from $24.1 million in Q1 2002 to $14.7 million in Q1 2003. The reduction was largely due to a $10.0 million non-cash charge in Q1 2002 related to warrants issued to Amgen, which did not recur in 2003.
• Improved Net Loss: Despite lower revenues, the net loss improved by approximately $5.4 million compared to the prior year, primarily due to the absence of the non-cash warrant expense and cost-cutting measures.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Strategic Focus: Management is pivoting to focus resources on biopharmaceutical discovery, specifically the lead candidate alfimeprase, which successfully completed Phase I trials. Phase II trials are planned for the first half of 2003.
• Asset Monetization: The company intends to out-license or partner non-core assets, including its microarray business and pharmacogenomic technology, to fund operations.
• Cash Runway: Management expects available cash to fund operations through 2004, contingent on cost control measures (hiring freeze, capital expenditure freeze) and successful monetization of non-core assets.

Risks and Contingencies

• Delisting Risk: The company's stock price has traded below the $1.00 minimum required for Nasdaq National Market listing. Failure to maintain the price could result in delisting, impairing access to capital markets.
• Financing Needs: The company has not achieved profitability and has an accumulated deficit of $167.0 million. Additional financing may be required before the end of 2004 if monetization efforts fail.
• Legal Proceedings: Nuvelo is defending a securities class action lawsuit inherited from Variagenics regarding alleged underwriter commissions in Variagenics' 2000 IPO.
• Lease Obligations: The company has significant future rental commitments totaling $59.3 million over the next several years.

Investor Verification Checklist

• Stock Price Compliance: Verify current trading price relative to the $1.00 Nasdaq minimum listing requirement.
• Alfimeprase Progress: Confirm the initiation and status of Phase II clinical trials for alfimeprase in peripheral arterial occlusion (PAO) and catheter occlusion.
• Non-Core Asset Monetization: Monitor announcements regarding the licensing or sale of the Callida Genomics (microarray) and pharmacogenomics businesses.
• Debt Covenants: Review terms of the $11.0 million line of credit with the Chairman and the $4.0 million note payable to Affymetrix, specifically regarding conversion rights and market capitalization triggers.
• Legal Status: Track developments in the Variagenics securities class action lawsuit.